Nuveen
DNTH icon

Nuveen’s Dianthus Therapeutics DNTH Stock Holding History

Nuveen’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Sell
119,460
-98,022
-45% -$8.56M ﹤0.01% 1593
2026
Q1 		$18.3M Buy
217,482
+26,867
+14% +$1.56M ﹤0.01% 1190
2025
Q4 		$7.86M Buy
190,615
+147,374
+341% +$5.71M ﹤0.01% 1697
2025
Q3 		$1.7M Sell
43,241
-4,452
-9% -$114K ﹤0.01% 2364
2025
Q2 		$889K Sell
47,693
-16,688
-26% -$313K ﹤0.01% 2664
2025
Q1 		$1.17M Sell
64,381
-1,470
-2% -$32.4K ﹤0.01% 2576
2024
Q4 		$1.44M Hold
65,851
– – ﹤0.01% 2527
2024
Q3 		$1.8M Sell
65,851
-20,920
-24% -$583K ﹤0.01% 2465
2024
Q2 		$2.25M Buy
+86,771
New +$2.09M ﹤0.01% 2326
2022
Q2 		– Sell
-4,417
Closed -$238K – 3307
2022
Q1 		$238K Hold
4,417
– – ﹤0.01% 3158
2021
Q4 		$339K Sell
4,417
-1,168
-21% -$117K ﹤0.01% 3154
2021
Q3 		$697K Buy
5,585
+81
+1% +$9.44K ﹤0.01% 3103
2021
Q2 		$861K Sell
5,504
-3,059
-36% -$562K ﹤0.01% 3058
2021
Q1 		$1.62M Sell
8,563
-416
-5% -$70K ﹤0.01% 2710
2020
Q4 		$1.13M Buy
8,979
+949
+12% +$108K ﹤0.01% 2757
2020
Q3 		$873K Buy
8,030
+3,938
+96% +$467K ﹤0.01% 2741
2020
Q2 		$492K Sell
4,092
-134
-3% -$18.9K ﹤0.01% 2903
2020
Q1 		$425K Buy
4,226
+1,004
+31% +$186K ﹤0.01% 2826
2019
Q4 		$782K Sell
3,222
-104
-3% -$19.4K ﹤0.01% 2774
2019
Q3 		$546K Hold
3,326
– – ﹤0.01% 2916
2019
Q2 		$785K Buy
+3,326
New +$822K ﹤0.01% 2832

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Nuveen's DNTH Position: Q2 2026 in Review

Nuveen reduced its Dianthus Therapeutics (DNTH) stake by 45% in Q2 2026, selling an estimated $8.56M and leaving 119,460 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

Nuveen first reported a position in DNTH in Q2 2019 and has held it in 21 quarters since. The position peaked at $18.3M in Q1 2026. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Nuveen held 119,460 shares of Dianthus Therapeutics worth $11.6M as of Q2 2026.
  • Nuveen sold 98,022 Dianthus Therapeutics shares in Q2 2026, an estimated $8.56M.
  • Dianthus Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1593 holding.
  • Nuveen first reported a position in Dianthus Therapeutics in Q2 2019 and has held it in 21 quarters since.
  • Nuveen's Dianthus Therapeutics position peaked at $18.3M in Q1 2026.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.